Skip to main content
Clinical Trials/NCT04120298
NCT04120298
Active, not recruiting
Not Applicable

Effects of Structured and Individualized Exercise in Patients With Metastatic Breast Cancer on Fatigue and Quality of Life

UMC Utrecht1 site in 1 country357 target enrollmentJanuary 8, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Metastatic Breast Cancer
Sponsor
UMC Utrecht
Enrollment
357
Locations
1
Primary Endpoint
Cancer-related physical fatigue
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

Currently, the effect of exercise on metastatic breast cancer has not been extensively studied, even though the benefits are evident in the curative setting. The investigators designed the EFFECT study to assess the effects of a 9-month structured and individualised exercise intervention in 350 patients with metastatic breast cancer (stage IV) on cancer-related physical fatigue, Health-Related Quality of Life (HRQoL), and other disease and treatment-related side effects at six months (primary endpoint).

Detailed Description

The EFFECT study is a multicentre, randomised controlled trial. The intervention group will participate in a 9-month exercise intervention. The exercise program will start with a 6-month period, where patients participate in a supervised multimodal exercise program twice a week supplemented with unsupervised exercises. The multimodal exercise program comprises aerobic-, resistance- and balance components. After completing the initial six-month period, one supervised session will be replaced by one unsupervised session until month nine. Unsupervised exercises will be supported by an activity tracker (FitBit) and an exercise App specifically designed for the EFFECT trial. Patients randomized to the control group will also receive an activity tracker (like the intervention group). The investigators will advice control patients to avoid inactivity and be as physically active as current abilities and conditions allow, with the aim to progress towards being physically active for 150min/week in line with the current exercise guidelines.

Registry
clinicaltrials.gov
Start Date
January 8, 2020
End Date
July 1, 2027
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr. Anne May

Cancer Epidemiologist

UMC Utrecht

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of breast cancer stage IV
  • ECOG (Eastern Cooperative Oncology Group scale) performance status ≤ 2
  • Able and willing to perform the exercise program and wear the activity tracker

Exclusion Criteria

  • A potential subject who meets any of the following criteria is not eligible for enrolment into this study:
  • Unstable bone metastases inducing skeletal fragility as determined by the treating clinician
  • Untreated symptomatic known brain metastasis
  • Estimated life expectancy \< 6 months as determined by the treating clinician
  • Serious active infection
  • Too physically active (i.e. \>210 minutes/week of moderate-to-vigorous intentional exercise
  • Severe neurologic or cardiac impairment according ACSM criteria
  • Uncontrolled severe respiratory insufficiency as determined by the treating clinician or if the patient is dependent on oxygen suppletion in rest or during exercise
  • Uncontrolled severe pain
  • Any other contraindications for exercise as determined by the treating physician

Outcomes

Primary Outcomes

Cancer-related physical fatigue

Time Frame: 0- 6 months (measured at baseline, 3 and 6 months)

Physical fatigue measured with the EORTC QLQ-FA12

Health-related Quality of Life

Time Frame: 0- 6 months (measured at baseline, 3 and 6 months)

Disease specific HRQoL measured with the EORTC QLQ-C30 Summary Score

Secondary Outcomes

  • Physical performance(0-6 months)
  • Physical fitness(0-6 months)
  • Intervention costs(0-9 months)
  • Satisfaction with exercise intervention(0-9 months)
  • Pain: severity and its impact on functioning.(0-9 months)
  • Treatment-related toxicities grade≥3(0-9 months)
  • Weight(0-6 months)
  • Height(0-6 months)
  • Waist circumference(0-6 months)
  • Neuropathic pain(0-9 months)
  • Pain Catastrophizing(0-9 months)
  • Sleep(0-9 months)
  • Separate HRQoL domains and Summary Score(0-9 months)
  • Cancer-related fatigue(0-9 months)
  • Breast cancer specific symptoms(0-9 months)
  • Anxiety, depression(0-9 months)
  • Physical activity (objective)(0-6-9 months)
  • Body composition (fat free mass and fat mass)(0-6 months)
  • Physical activity (subjective)(0-6-9 months)
  • Resting heart rate(0-6 months)
  • Blood pressure(0-6 months)
  • Work status/ healthcare resources consumption(0-9 months)
  • Cancer treatment(0-9 months)
  • Quality of working life(0-9 months)
  • Health status(0-9 months)
  • Disease control(0-9 months)
  • Biomarkers (systemic inflammation, growth factors, blood/brain barrier modulators)(0-6 months)

Study Sites (1)

Loading locations...

Similar Trials